Drugs / radionuclide therapy with [177Lu]Lu--TEFAPI-06
radionuclide therapy with [177Lu]Lu--TEFAPI-06
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07299253 | Aug 2023 → Aug 2024 | metastatic malignant neoplasm | Lanzhou University Second Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | radionuclide therapy with [177Lu]Lu--TEFAPI-06 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07299253 ↗ |
| Action | Inhibit | “fibroblast activation protein inhibitor (FAPI) radiopharmaceutical” NCT07299253 ↗ |
| Modality | Other / unclassified | “FAPI radiopharmaceutical” NCT07299253 ↗ |